Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 12/2012

01-12-2012 | Literatur kommentiert

Kein Vorteil für die Gesamtgruppe der Mammakarzinompatientinnen durch adjuvante Therapie mit Zoledronsäure

Author: Prof. Dr. R. Souchon

Published in: Strahlentherapie und Onkologie | Issue 12/2012

Login to get access

Auszug

Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187–195 …
Literature
1.
Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187–195PubMedCrossRef
2.
Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomized, phase II trial. Lancet Oncol 11:421–428PubMedCrossRef
3.
Neville-Webbe HL, Coleman RE, Holen I (2010) Combined effects of bisphosphonate, zoledronic acid and aromatase inhibitor letrozol on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 102:1010–1017PubMedCrossRef
4.
Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 3.0, Aktualisierung 2012. AWMF-Register-Nummer: 302–0450L
5.
Guidelines of the AGO Breast Committee 2012, Version 1. Herausgegeben von der Kommission Mamma der AGO (vertreten durch: Anton Scharl) Update 2012. AGO Breast Committee. Deutsche Version 2012 vs1. http://​www.​ago-online.​org/​Leitlinien
Metadata
Title
Kein Vorteil für die Gesamtgruppe der Mammakarzinompatientinnen durch adjuvante Therapie mit Zoledronsäure
Author
Prof. Dr. R. Souchon
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 12/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0252-7

Other articles of this Issue 12/2012

Strahlentherapie und Onkologie 12/2012 Go to the issue

Literatur kommentiert

Axilladissektion vs. keine Axilladissektion bei Frauen mit invasivem Brustkrebs und positiven Sentinellymphknoten

Originalien

Datenbankbasierte digitale retrospektive Auswertung von Patientenkollektiven in der Radioonkologie

Original article

HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation

Original article

Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function

Original article

Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors

Original article

Benign painful shoulder syndrome